- Jul 12, 2021
Aravax presents PVX108 Phase 1 longitudinal immunology data at EAACI 2021.
13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page